Promising c. diff drug fails to prove benefit in small, halted trial
NCT ID NCT03756454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether an extra dose of bezlotoxumab, a drug that blocks the harmful toxin made by C. diff bacteria, could help very sick patients recover after emergency colon surgery. Only 5 people took part before the study was stopped early. The goal was to see if the drug could lower the risk of death and organ failure, but there were too few participants to draw clear conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIA DIFFICILE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University
Columbus, Ohio, 43210, United States